170 related articles for article (PubMed ID: 24365641)
1. Biosimilars in Crohn's disease.
Scheinberg M
J Crohns Colitis; 2014 Jul; 8(7):710. PubMed ID: 24365641
[No Abstract] [Full Text] [Related]
2. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach.
Peyrin-Biroulet L; Danese S; Cummings F; Atreya R; Greveson K; Pieper B; Kang T
Expert Rev Gastroenterol Hepatol; 2019 Aug; 13(8):731-738. PubMed ID: 31322440
[No Abstract] [Full Text] [Related]
3. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
Scheinberg M; Castañeda-Hernández G
Arthritis Res Ther; 2014 Dec; 16(6):501. PubMed ID: 25677586
[TBL] [Abstract][Full Text] [Related]
4. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
Danese S; Fiorino G; Michetti P
J Crohns Colitis; 2014 Nov; 8(11):1548-50. PubMed ID: 25008477
[TBL] [Abstract][Full Text] [Related]
5. Review of Biosimilars of Adalimumab.
Kaushik VV
J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars for Management of Crohn Disease.
Nielsen OH; Ainsworth MA
Ann Intern Med; 2019 Jan; 170(2):129-130. PubMed ID: 30535358
[No Abstract] [Full Text] [Related]
7. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
8. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
[TBL] [Abstract][Full Text] [Related]
10. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.
Berns M; Hommes DW
Expert Opin Investig Drugs; 2016; 25(2):129-43. PubMed ID: 26616476
[TBL] [Abstract][Full Text] [Related]
12. Etanercept biosimilar SB-4.
Pelechas E; Drosos AA
Expert Opin Biol Ther; 2019 Mar; 19(3):173-179. PubMed ID: 30616405
[TBL] [Abstract][Full Text] [Related]
13. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars in Crohn's Disease and Ulcerative Colitis.
Wolf DC
Inflamm Bowel Dis; 2016 Apr; 22(4):994-7. PubMed ID: 26933749
[No Abstract] [Full Text] [Related]
15. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
[TBL] [Abstract][Full Text] [Related]
16. Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability.
Cozijnsen MA; Samsom JN; de Ridder L
Paediatr Drugs; 2018 Feb; 20(1):19-28. PubMed ID: 29079905
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial development for biosimilars.
Alten R; Cronstein BN
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
[TBL] [Abstract][Full Text] [Related]
18. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
Danese S; Fiorino G; Michetti P
J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet.
Rychlick N
Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768
[TBL] [Abstract][Full Text] [Related]
20. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
